Potential implications of practice effects in Alzheimer's disease prevention trials

Alzheimer's and Dementia: Translational Research and Clinical Interventions - Tập 3 - Trang 531-535 - 2017
Diane M. Jacobs1,2, M. Colin Ard2,3, David P. Salmon1,2, Douglas R. Galasko1,2, Mark W. Bondi2,4,5, Steven D. Edland1,2,3
1Department of Neurosciences, University of California–San Diego, La Jolla, CA, USA;
2Shiley-Marcos Alzheimer's Disease Research Center, La Jolla, CA, USA
3Division of Biostatistics, Department of Family Medicine & Public Health, University of California San Diego, La Jolla, CA, USA
4Department of Psychiatry, University of California, San Diego, La Jolla, CA USA
5Veteran Affairs San Diego Healthcare System, San Diego, CA, USA

Tóm tắt

AbstractIntroductionPractice effects (PEs) present a potential confound in clinical trials with cognitive outcomes. A single‐blind placebo run‐in design, with repeated cognitive outcome assessments before randomization to treatment, can minimize effects of practice on trial outcome.MethodsWe investigated the potential implications of PEs in Alzheimer's disease prevention trials using placebo arm data from the Alzheimer's Disease Cooperative Study donepezil/vitamin E trial in mild cognitive impairment. Frequent ADAS‐Cog measurements early in the trial allowed us to compare two competing trial designs: a 19‐month trial with randomization after initial assessment, versus a 15‐month trial with a 4‐month single‐blind placebo run‐in and randomization after the second administration of the ADAS‐Cog. Standard power calculations assuming a mixed‐model repeated‐measure analysis plan were used to calculate sample size requirements for a hypothetical future trial designed to detect a 50% slowing of cognitive decline.ResultsOn average, ADAS‐Cog 13 scores improved at first follow‐up, consistent with a PE and progressively worsened thereafter. The observed change for a 19‐month trial (1.18 points) was substantively smaller than that for a 15‐month trial with 4‐month run‐in (1.79 points). To detect a 50% slowing in progression under the standard design (i.e., a 0.59 point slowing), a future trial would require 3.4 times more subjects than would be required to detect the comparable percent slowing (i.e., 0.90 points) with the run‐in design.DiscussionAssuming the improvement at first follow‐up observed in this trial represents PEs, the rate of change from the second assessment forward is a more accurate representation of symptom progression in this population and is the appropriate reference point for describing treatment effects characterized as percent slowing of symptom progression; failure to accommodate this leads to an oversized clinical trial. We conclude that PEs are an important potential consideration when planning future trials.

Tài liệu tham khảo

10.1097/JGP.0b013e318209dd3a 10.1037/neu0000208 10.1016/j.dadm.2014.11.003 10.1080/13854046.2012.680913 10.1093/aje/kwv212 10.1016/j.acn.2004.12.003 10.1207/S15324826AN0804_4 10.1076/jcen.20.3.339.822 McCaffrey R.J., 1992, Neuropsychological and physical side effects of metoprolol in essential hypertensives, Neuropsychology, 6, 225, 10.1037/0894-4105.6.3.225 10.1056/NEJM198812153192404 10.1002/mds.25750 10.1056/NEJMoa050151 10.1001/archneur.56.3.303 10.1097/00002093-199700112-00003 10.3233/JAD-2011-0062 M.C.Donohue A.C.Gamst S.D.Edland.Sample Size Calculations for Longitudinal Data. Longpower: Power and Sample Size Calculators for Longitudinal Data R Package Version 1.0–16.2016 Available at:Https://cran.r‐Project.org/web/packages/longpower/longpower.pdf Accessed September 19 2017 10.1001/jamaneurol.2014.803 10.1016/j.trci.2016.05.002 10.1080/13854046.2016.1241303 10.1080/13854046.2013.836567
Thông tin
Thông tin xuất bản

Alzheimer's and Dementia: Translational Research and Clinical Interventions

Tập 3

531-535

Thông tin tác giả